

Ranolazine preserves and improves left ventricular ejection fraction and autonomic measures when added to guideline-driven therapy in chronic heart failure

Gary L. Murray¹, Joseph Colombo²

¹The Heart and Vascular Institute, Germantown, TN - USA

²Department of Cardiology, Drexel University College of Medicine, and ANSAR Medical Technologies, Inc., Philadelphia, PA - USA

ABSTRACT

Background: Ranolazine (RAN) reduces cardiac sodium channel 1.5's late sodium current in congestive heart failure (CHF), reducing myocardial calcium overload, potentially improving left ventricular (LV) function. RAN blocks neuronal sodium channel 1.7, potentially altering parasympathetic and sympathetic (P&S) activity. The effects of RAN on LV ejection fraction (LVEF) and P&S function in CHF were studied.

Methods: Matched CHF patients were given open-label RAN (1000 mg po-bid) added to guideline-driven therapy (RANCHF, 41 systolic, 13 diastolic) or no adjuvant therapy (control, NORANCHF, 43 systolic, 12 diastolic). Echocardiographic LVEF and P&S measures were obtained at baseline and follow-up (mean 23.7 months).

Results: LVEF increased in 70% of RANCHF patients, an average of 11.3 units. Mean LVEF remained unchanged in NORANCHF patients. P&S measures indicated cardiovascular autonomic neuropathy ($P \leq 0.1 \text{ bpm}^2$) in 20% of NORANCHF patients at baseline and in 29% at follow-up (increasing in both groups). At baseline, 28% of patients had high sympathovagal balance (SB), RAN normalized SB over 50% of these; in contrast, the NORANCHF group had a 20% increase in patients with high SB.

Conclusions: RAN preserves or improves LVEF and decreases high SB in CHF.

Keywords: Congestive heart failure, Left ventricular ejection fraction, Parasympathetic function, Patient outcomes, Ranolazine, Sympathetic function

Introduction

Despite advances in pharmacologic management (1-5) and device therapy (6), improvement in left ventricular (LV) function in congestive heart failure (CHF) patients, while statistically significant, remains relatively mild in many subjects. The late sodium current (I_{Na}) present in CHF causes an intramyocardial calcium (Ca^{++}) overload that results in diastolic dysfunction and microvascular compression that can worsen LV function (7). RAN binds to amino acid F1760 of the cardiac sodium channel 1.5 ($Na_{v1.5}$), thereby reducing the late I_{Na} . In a therapeutic concentration (6 μmol), intramyocardial Ca^{++} overload is reduced 50%. Additionally, RAN blocks neuronal sodium channel 1.7 ($Na_{v1.7}$) in a strongly use-dependent manner via the local anesthetic receptor

(8, 9). Therefore, RAN may directly alter function of the parasympathetic and sympathetic (P&S) branches of the autonomic nervous system (ANS). We postulated these actions of RAN should result in favorable changes in LV function and P&S measures in CHF.

Methods

Subjects and experimental regimen

One hundred and nine systolic or diastolic, New York Heart Association (NYHA) class 2-4 CHF patients were included in this study. They were treated according to standard heart failure guidelines (10). In an open-label fashion, patients were prescribed Ranolazine (RAN, 1000 mg po-bid) in addition to standard heart failure therapy (RANCHF, 41 systolic, 13 diastolic) or no adjuvant therapy (control, NORANCHF, 43 systolic, 12 diastolic), in an unblinded fashion. Patients were matched for age, gender and history. Patient demographics are presented in Table I. Since patients were on maximally tolerated doses of beta-blocker and angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blockers (ARBs), only the diuretic dose was adjusted as needed.

Diastolic CHF is defined as CHF with LV ejection fraction (LVEF) ≥ 0.40 . Baseline 2D-echocardiograms were obtained and the LVEF calculated as the average of the apical 2 and 4

Accepted: August 21, 2014

Published online: December 22, 2014

Corresponding author:

Gary L. Murray
Director, The Heart and Vascular Institute
7205 Wolf River Blvd
Germantown
TN, 38138, USA
drglmurray@hotmail.com

TABLE I - Patient demographics

	Systolic CHF (LVEF <0.40)		Diastolic CHF (LVEF ≥0.40)	
	RAN (N = 41)	NORAN (N = 43)	RAN (N = 13)	NORAN (N = 12)
Age (mean)	61	63	67	63
Gender (F, M)	20, 21 (48.8%, 51.2%)	28, 15 (44.4%, 55.6%)	5, 8 (38.5%, 61.5%)	6, 6 (50.0%, 50.0%)
Comorbidities				
CAD	21 (51.2%)	24 (55.8%)	7 (53.8%)	6 (50.0%)
Diabetes, type 2	14 (34.1%)	12 (27.9%)	5 (38.5%)	5 (41.7%)
Hypertension	20 (48.8%)	24 (55.8%)	13 (100%)	9 (75.0%)
CRD	6 (14.6%)	4 (9.3%)	3 (23.1%)	0
Therapy				
Amiodarone	7 (17.1%)	5 (11.6%)	0	0
Beta-blocker	40 (97.6%)	42 (97.7%)	13 (100%)	12 (100%)
Carvedilol (ave mg/d)	34	42	34	49
Metoprolol (ave mg/d)	100	200	133	200
BiV PCD	14 (34.1%)	16 (37.2%)	0	0
PCD	5 (12.2%)	3 (7.0%)	0	0
ACE-I	33 (80.5%)	38 (88.4%)	9 (69.2%)	0
Aldosterone Ant.	23 (56.1%)	18 (41.9%)	7 (53.8%)	4 (33.3%)
Follow-up (months, ave.)	24.0	20.2	25.0	25.5
NYHA Class		2	3	4
RAN syst		15 (36.0%)	23 (56.0%)	3 (7.0%)
RAN dias		8 (62.0%)	5 (38.0%)	0
NORAN syst		19 (44.0%)	21 (49.0%)	3 (7.0%)
NORAN dias		9 (75.0%)	3 (25.0%)	0

ACE-I = angiotensin-converting enzyme inhibitor; Ant = antagonist; ave = average; BiV PCD = bi-ventricular pacing cardiac defibrillator; CAD = coronary artery disease; CHF = congestive heart failure; CRD = chronic renal disease; dias = diastolic; mg/d = milligrams per day; NORAN = no Ranolazine; NYHA = New York Heart Association; PCD = pacing cardiac defibrillator; RAN = Ranolazine; syst = systolic.

chamber Simpson's method (11), and studies were repeated within 36 months (mean follow-up for RANCHF patients is 24.5 months and for NORANCHF 22.8 months, Tab. II). The accuracy of the initial echocardiographic LVEF was confirmed by being within 5 ejection fraction units (EFUs) of the LVEF as measured by nuclear multigated acquisition.

Serial changes in any patient of $\geq \pm 7$ EFUs are considered clinically significant (12). Other measurements are per American Society of Echocardiography guidelines (13). CHF is classified as systolic or diastolic, rather than CHF with preserved (normal) LVEF or reduced LVEF, because the RANCHF group only had one subject with a normal LVEF.

P&S function in response to Ewing challenges (14) was assessed noninvasively using the ANSAR Medical Technologies, Inc., Philadelphia, PA, ANX 3.0 Autonomic Function Monitor. P&S activity was computed simultaneously and independently based on concurrent, continuous time-frequency analyses of respiratory activity (RA) and heart rate variability (HRV) (15-19). Parasympathetic activity (measured as the respiratory frequency area, RFa) is defined as the spectral power within a 0.12 Hz-wide window centered on the fundamental respiratory frequency (FRF) in the HRV spectrum. FRF is identified as the peak spectral mode from time-frequency analysis of RA. Effectively, FRF is a measure of vagal outflow as

it effects the heart (a measure of cardiovagal activity). Sympathetic activity (low-frequency area, LFa) is defined as the remaining spectral power, after computation of RFa, in the low-frequency window (0.04-0.15 Hz) of the HRV spectrum. High sympathovagal balance (SB = LFa/RFa) is defined as a resting LFa/RFa ratio >3.0 (established in our laboratory by evaluating 260 healthy volunteers) (11). P&S activity was recorded from a standard autonomic test, including 5 minutes rest, 1 minute paced breathing (6 breaths/min), a Valsalva challenge (including a 15-sec Valsalva maneuver) and a quick stand followed by 5 minutes of quiet stand. The average SB reported is the average of the ratios recorded during the sampling period, not a ratio of averages (11).

Cardiovascular autonomic neuropathy (CAN) was defined in standard fashion (20, 21), reflecting very low, resting RFa (<0.1 bpm²) (22). The P&S method is valid regardless of challenge or patient state or history. Normal SB is $0.4 < SB < 3.0$ as validated in our lab with 260 healthy volunteers. High SB (>3.0) and CAN define a high mortality risk, including silent MI, sudden cardiac death and acute coronary syndrome (ACS) (15, 16, 23-25). Records including high-quality arrhythmia are omitted. P&S and HRV measures are correlated with outcomes. While the patient population is underpowered to make final health outcome assessments, we determined

TABLE II - Echocardiographic results

	Systolic CHF		Diastolic CHF	
	RAN (N = 41)	NORAN (N = 43)	RAN (N = 13)	NORAN (N = 12)
LVIDd (ave.±st. dev., cm)				
Initial	5.88 ± 0.82	6.09 ± 0.74	5.16 ± 0.71	5.28 ± 0.83
Final	5.84 ± 0.82	6.11 ± 0.77	5.26 ± 0.46	5.47 ± 0.95
Δp	0.679	0.831	0.543	0.637
LAD (ave.±st. dev., cm)				
Initial	4.59 ± 0.73	4.51 ± 0.67	4.20 ± 0.88	4.11 ± 0.65
Final	4.33 ± 0.64	4.44 ± 0.62	4.30 ± 0.71	4.28 ± 0.54
Δp	0.084	0.821	0.785	0.504
LVIDs (ave.±st. dev., cm)				
Initial	4.94 ± 0.81	5.21 ± 0.63	4.08 ± 0.64	4.03 ± 0.67
Final	4.70 ± 0.85	5.11 ± 0.77*	4.00 ± 0.84	4.36 ± 0.99
Δp	0.245	0.924	0.882	0.346
LVEF (ave.±st. dev., %)				
Initial	30.46 ± 5.66	30.17 ± 5.68	42.83 ± 3.46	47.50 ± 5.94
Final	36.83 ± 9.97	29.20 ± 7.27**	52.33 ± 8.59	47.00 ± 9.35
Δp	0.018	0.586	0.002	0.875

CHF = congestive heart failure; LAD = left atrial diameter; LVEF = left ventricular ejection fraction; LVIDd = left ventricular internal diameter diastole; LVIDs = left ventricular internal diameter systole; NORAN = no Ranolazine; Δp = significance of change from initial to final; RAN = Ranolazine.

*p<0.001; **p = 0.013.

the occurrence of major adverse cardiac events (MACE), defined as cardiac death (determined from hospital records or death certificates), heart failure hospitalization and ventricular tachycardia or fibrillation (as determined by defibrillator therapy, or administration of intravenous amiodarone for arrhythmia termination) alone or as a composite endpoint. All subjects signed appropriate informed consent forms for the studies and treatments rendered.

Statistical analyses

Continuous data were assessed for normality with normally distributed data analyzed using Student *t*-tests and non-normally distributed data assessed using a Mann-Whitney test. Dichotomous data were analyzed using the Chi-square test or Fischer's Exact Test. A *p*-value of ≤0.05 was considered significant. We determined that we needed 50 patients per group to have a sufficient sample size using an alpha of 0.05, difference of means of 6 units and expected standard deviation of 15 units with a power of 80%. All statistics are performed under SPSS v 1.4. Student *t*-tests are performed as two-tailed with equal variance. Significance values are determined on the null hypothesis that pre- and posttreatment values are equal.

Results

Overall, 109 age-, gender- and history-matched CHF patients already treated according to standard heart failure guidelines (10) were included in the study, with 54 patients receiving RAN and 55 patients in the control group. Demographic comparisons are provided in Table I and are similar between

TABLE III - Changes in LVEF

	ΔEFU ≤-7	-6≤ΔEFU ≤+6	ΔEFU ≥+7	p
RANCHF (N = 54)	1 (2%)	27 (50%)	26 (48%)	<0.001
NORANCHF (N = 55)	8 (15%)	43 (78%)	4 (7%)	<0.001

Δ = change; CHF = congestive heart failure; EFU = ejection fraction units; LVEF = left ventricular ejection fraction; NORANCHF = CHF patients not prescribed Ranolazine; RANCHF = CHF patients prescribed Ranolazine.

groups: 93% of the patients are evenly divided between NYHA class 2 and 3; 98% are on a beta-blocker (NORANCHF subjects at a slightly higher dose). Slightly more diastolic RANCHF patients have hypertension and chronic renal insufficiency.

Left ventricular ejection fraction

On follow-up, RANCHF patients had significantly higher LVEF (Tab. II; systolic CHF: *p*<0.001, diastolic CHF: *p* = 0.003). Controls had no significant change in the mean LVEF. When viewed dichotomously (Tab. III), 26/54 (48%) RANCHF patients experienced a clinically significant increase in LVEF (≥+7 EFU) as compared to 4/55 controls (7%, *p*<0.001, Tab. III). From the systolic RANCHF subgroup, 17/41 (41%) subjects experienced a clinically significant increase (>7 EFUs) in LVEF as compared to 9/13 (69%) diastolic RANCHF patients (*p*<0.001). Final LVEF in cohort patients experiencing MACE was significantly lower than in those who were MACE-



free (Tabs. IV and V, $p = 0.005$). In the RANCHF group MACE subpopulation, the initial to final LVEF increase was less than in patients without MACE, 6 EFUs vs. 9 EFUs (Tab. IV, $p < 0.020$). In control patients, insignificant changes in LVEF occurred regardless of MACE or not ($p > 0.050$).

Other echocardiographic data

Systolic RANCHF patients demonstrated a decrease in left ventricular internal dimension in systole (LVIDs). Diastolic RANCHF patients demonstrated a slight increase in LVID-diastole (LVIDd) coupled with a slight decrease in LVIDs. Baseline LVID (Tab. II) trended similar between groups ($p > 0.050$). LVIDd averaged 5.88 and 6.09 cm for systolic RANCHF and NORANCHF patients, and 5.16 and 5.28 cm for diastolic RANCHF and NORANCHF patients, respectively. LVIDs averaged 4.94 and 5.21 cm for systolic RANCHF and NORANCHF patients, and 4.08 and 4.03 cm for diastolic RANCHF and NORANCHF patients, respectively. RANCHF vs. NORANCHF patients had significantly lower LVIDs at follow-up (> 0.36 cm, $p < 0.001$, Tab. II). No significant differences ($p > 0.050$) in baseline or follow-up LVIDd or LAD occurred between experimental groups, although LAD tended to decrease in the systolic RANCHF cohort (4.6 to 4.3 cm, Tab. II, $p = 0.084$).

Autonomic (P&S and HRV) measures

Arrhythmia-free, P&S studies were accomplished every 6 months for 95/109 (87%) patients; 13% of the patients

(8 RANCHF and 6 NORANCHF) had arrhythmias precluding a complete assessment. While P&S measures are readable (26), HRV analyses are contraindicated for arrhythmia (27). Autonomic measures of the RANCHF and control groups are presented in Table VI. The average RANCHF patient demonstrated significant P&S responses to RAN ($p \leq 0.050$), except for paced breathing RFa (a parasympathetic stimulus; $p = 0.065$). This included significant reductions in absolute and relative measures of sympathetic activity. None of the Time Domain Ratio responses to RAN were significant ($p \geq 0.050$). The absolute and relative resting sympathetic changes from baseline to follow-up in the control patients were also significant.

Sympathetic activity remained high for cohort patients with events (Tabs. IV and V), even though SB demonstrated a relative decrease from 6.25 to 4.86 (unitless). The high pre-RAN SB (higher than the ratio of the averages might suggest, Tab. IV) is due to two patients with severe CAN. Post-RAN, these patients were found to no longer be in CAN and demonstrated an increase of ≥ 7 EFUs, on average ($p = 0.0002$). The parasympathetic response to deep breathing is slight. The change in RFa is well correlated with the changes in LVEF ($p < 0.001$). The exhalation to inhalation (E/I) ratio decreases (not significant). The sympathetics (LFa) decrease with Valsalva challenge. The VR decreases (not significant). The Valsalva challenge responses are well correlated with the changes in LVEF ($p < 0.001$). Sympathetic withdrawal (SW) was demonstrated by 9/15 RANCHF patients. These patients all demonstrated an abnormal BP response to standing. Upon follow-up, these patients demonstrated an average increase

TABLE IV - Baseline and follow-up (pre- and post-RAN) P&S measures and LVEF in 46[†] RANCHF patients with and without events. See text for details

	Pts w/Events* (N = 15)		Pts w/o Events (N = 31)	
	Pre- & Post-RAN	P (LVEF)	Pre- & Post-RAN	P (Bx)
Rest				
LFa	2.26 & 0.74	<0.001	1.87 & 1.05	0.011
RFa	1.04 & 0.19	<0.001	0.88 & 1.06	0.006
SB [‡]	6.18 & 3.04	<0.001	1.26 & 1.08	0.025
Deep breathing				
RFa	19.1 & 18.6	<0.001	6.57 & 14.0	0.011
E/I ratio	1.21 & 1.08	<0.636	1.08 & 1.10	0.321
Valsalva challenge				
LFa	39.7 & 21.0	<0.001	19.4 & 21.8	0.065
VR	1.55 & 1.28	<0.693	1.26 & 1.22	0.480
Head-up postural change challenge (Stand)				
LFa	0.83 & 1.81	<0.001	1.08 & 2.57	0.012
RFa	0.53 & 0.82	<0.001	0.86 & 3.01	0.045
30:15 ratio	1.15 & 1.23	0.120	1.12 & 1.12	0.329
Δ LVEF	0.30 to 0.36 (+6 EFUs)	0.018	0.35 to 0.44 (+6 EFUs)	0.005

bpm² = beats per min²; Δ = change; EFU = ejection fraction unit; E/I ratio = exhalation to inhalation ratio (unitless); HRV = heart rate variability; LFa = low-frequency area (bpm², a measure of sympathetic activity; see Methods); LVEF = left ventricular ejection fraction; RAN = Ranolazine; RANCHF = congestive heart failure patients treated with RAN; RFa = respiratory frequency area (bpm², a measure of parasympathetic activity; see Methods); SB = sympathovagal balance (=LFa/RFa, unitless); VR = Valsalva ratio (unitless); 30:15 ratio = ratio of 30th to the 15th R-R interval immediately after standing (unitless); p-value (LVEF) = significance based on correlation with Δ LVEF; p-value (Bx) = significance based on baseline (Bx) measure.

[†] = 8 RANCHF and 6 NORANCHF patients omitted from analysis due to high-quality arrhythmia preventing HRV-alone analysis.

+ = an event (VT/VF arrhythmia, CHF admission, or death; see Methods).

[‡] = an average of ratios, not a ratio of averages (see Methods).

TABLE V - Baseline and follow-up P&S measures and LVEF in 49[†] NORANCHF patients with and without events. See text for details

	Pts w/Events* (N = 17)		Pts w/o Events (N = 32)	
	Pre- & Post-RAN	P (LVEF)	Pre- & Post-RAN	P (Bx)
Rest				
LFa	2.10 & 7.55	0.013	1.62 & 1.58	0.002
RF*	0.46 & 1.30	0.011	0.84 & 0.69	0.002
SB‡	6.31 & 6.47	0.016	1.87 & 3.44	0.002
Deep breathing				
RFa	8.24 & 18.1	0.009	15.9 & 11.1	0.194
E/I ratio	1.08 & 1.16	0.013	1.15 & 1.09	0.302
Valsalva challenge				
LFa	5.81 & 13.3	0.015	24.2 & 11.0	0.278
VR	1.12 & 1.14	0.056	1.20 & 1.61	0.691
Head-up postural change challenge (Stand)				
LFa	6.80 & 1.19	0.013	1.02 & 1.24	0.042
RFa	1.09 & 0.70	0.061	4.09 & 0.66	0.026
30:15 ratio	1.15 & 1.12	0.057	1.17 & 1.31	0.116
ΔLVEF	0.287 to 0.278 (-0.9 EFUs)	0.005	0.368 to 0.370 (+0.2 EFUs)	0.028

EFU = ejection fraction unit; E/I ratio = exhalation to inhalation ratio (unitless); HRV = heart rate variability; LFa = low-frequency area (bpm²), a measure of sympathetic activity (see Methods); LVEF = left ventricular ejection fraction; RAN = Ranolazine; RANCHF = congestive heart failure patients treated with RAN; RFa = respiratory frequency area (bpm²), a measure of parasympathetic activity (see Methods); SB = sympathovagal balance (unitless, see Methods); VR = Valsalva ratio (unitless, see Methods); 30:15 ratio = ratio of 30th to the 15th R-R interval immediately after standing (unitless, see Methods).

[†] = 6 patients omitted from analysis due to high-quality arrhythmia preventing HRV-alone analysis.

TABLE VI - Baseline and follow-up P&S measures and LVEF from age-, gender- and history-matched, arrhythmia-free patients: RANCHF vs. NORANCHF. See text for details

	RANCHF (N = 46)			NORANCHF (N = 49)		
	Initial	Final	p	Initial	Final	p
Rest						
LFa	4.91	2.49	0.034	1.74	3.42	0.015
RFa	1.64	1.56	0.047	0.70	0.93	0.012
SB	2.42	1.98	0.019	2.61	4.28	0.039
Deep breathing						
RFa	15.8	13.7	0.065	7.66	11.8	0.267
E/I ratio	1.11	1.09	0.552	1.11	1.11	0.156
Valsalva challenge						
LFa	35.6	29.0	0.050	17.8	11.8	0.187
VR	1.20	1.24	0.359	1.17	1.19	0.753
Head-up postural change challenge (Stand)						
LFa	2.63	2.13	0.006	2.83	1.28	0.011
RFa	2.20	0.76	0.002	0.82	0.90	0.011
30:15 ratio	1.16	1.09	0.075	1.16	1.17	0.068
LVEF	0.34	0.41	0.0002	0.38	0.34	0.125

bpm² = beats per min²; EFU = ejection fraction unit; E/I ratio = exhalation to inhalation ratio (unitless); LFa = low-frequency area (bpm²), a measure of sympathetic activity (see Methods); LVEF = left ventricular ejection fraction; RAN = Ranolazine; RANCHF = congestive heart failure patients treated with RAN; RFa = respiratory frequency area (bpm²), a measure of parasympathetic activity (see Methods); SB = sympathovagal balance (unitless, see Methods); VR = Valsalva ratio (unitless, see Methods); 30:15 ratio = ratio of 30th to the 15th R-R interval immediately after standing (unitless, see Methods).

in sympathetic activity (a normalized response) as compared with rest, with improved standing BP. Only four RANCHF patients continued to demonstrate SW after history of RAN. The stand responses are well correlated with changes in LVEF ($p < 0.001$).

For NORANCHF cohort patients (Tab. V), the relative sympathetic measure (SB) increased ($p < 0.05$). In the RANCHF group without events (Tab. IV), the relative measure (SB) decreased. These SB changes are significantly associated with changes in LVEF ($p < 0.001$). The associated average increase in LVEF is more than +9 EFUs. The patients without events started in balance (normal SB) and remained in balance. The resting changes are well correlated with the changes in LVEF ($p < 0.001$). The pre- and post-RAN resting P&S responses in both the subpopulations with and without events are significant ($p \leq 0.025$). The pre- and post-RAN deep breathing parasympathetic measures (RFa) in both the subpopulations with and without events are significant ($p \leq 0.011$), but not the increases in E/I ratio ($p > 0.321$). Nearly half (14/27) of the pre-RAN event patients demonstrated SW in response to stand, indicating orthostatic dysfunction. These findings are associated with abnormal blood pressure responses to stand. Post-RAN, the average patient without events reversed their SW. This is a normalized response. Only six patients continued to demonstrate SW after history of RAN. The pre- and post-RAN autonomic responses to stand in both subpopulations are significant ($p \leq 0.045$).

Table V presents baseline and follow-up P&S measures and LVEF in the NORANCHF patients with and without events. P&S changes were significant ($p \leq 0.050$) for patients with events. Their SB started high and increased upon follow-up. The patients without events demonstrated opposite absolute changes upon follow-up. However, the net result was an increase in SB to above normal. Only the E/I ratio change for the patients with events was significant ($p = 0.013$).

Health outcome assessment

The composite MACE endpoint occurred in 17/54 (31.5%) RANCHF patients and 21/55 (38.2%) control patients. When evaluated separately, each MACE endpoint was lower in the RANCHF patients.

Discussion

In the past 30 years, improvements in LV function and outcomes in systolic CHF have been attributed to pharmacologic therapy addressing the neurohumoral paradigm, together with the advent of device therapy (1-6). However, even more improvement is needed. This has triggered stem cell trials (28) and a search for new pharmacologic agents. To date, no therapy in diastolic CHF has shown improved survival. RAN is a first in class drug. It reduces the late sodium current (I_{Na}) resulting in a 50% reduction of the intramyocellular Ca^{++} overload caused by the late I_{Na} via the Na^+/Ca^{++} exchanger (7). This improves diastolic and microvascular dysfunction, and should result in improved LV systolic function (29). Since LVEF is widely accepted as one of the most important prognostic indicators in CHF (30), we focused on its changes after RAN was added to guideline-driven therapy. In therapeutic con-

centrations (2-6 μmol), RAN also inhibits neuronal $Na_{v1.7}$ via the local anesthetic receptor in a use-dependent fashion (8, 9). Consequently, RAN potentially can alter ANS function directly, improving P&S measures. High sympathetic tone (high SB) with critically low parasympathetic activity (CAN) indicates high mortality risk, and has been associated with sudden cardiac death, CHF and ACS (15-19, 31). This study is the first to correlate CHF outcomes with changes in both LVEF and P&S measures.

We found RAN significantly increased LVEF by 6.4 EFUs in systolic CHF patients and 9.5 EFUs in diastolic CHF (Tab. II). In the NORANCHF group, final LVEF fell 1 EFU in the systolic CHF patients and 0.5 EFU in the diastolic CHF patients (Tab. II). These LVEF changes represent mean values of the cohort groups. In the systolic RANCHF patients, the increase in LVEF was solely due to a decrease in LVIDs (Tab. II). In diastolic RANCHF patients, the increase in LVEF was due to a slight increase in LVIDd (suggesting increased diastolic filling) coupled with a slight decrease in LVIDs (suggesting improved systolic emptying; Tab. II). Individually, only 1/54 (2%) RANCHF patients decreased LVEF by ≤ -7 EFUs, and 26/54 (48%) RANCHF patients increased LVEF by $\geq +7$ EFUs, with the remaining 50% of patients showing little LVEF change ($p < 0.001$, Tab. III). Increases in the RANCHF patients' LVEF were sufficient to avoid defibrillator implantation in 10 subjects, resulting in substantial cost savings. In the control group, 8/55 (15%) decreased LVEF by ≤ -7 EFUs, and only 4/55 (7%) patients increased LVEF by $\geq +7$ EFUs, with the remaining 43/55 (78%) demonstrating little change (Tab. III). Therefore, LVEF is more than 6 times as likely to increase and $1/8^{\text{th}}$ as likely to decrease following RAN therapy in CHF patients. LVEF can increase regardless of the initial LVEF. RAN increased LVEF by $\geq +7$ EFUs in 17/41 (41.5%) systolic CHF patients vs. 9/13 (69%) diastolic CHF patients ($p < 0.001$). Furthermore, when RAN increased LVEF by $\geq +7$ EFUs, 9/26 (35%) patients had a history of CAD, whereas 17/26 (65%) did not ($p < 0.001$). Since almost 80% of the CAD patients were revascularized, and only 14% had a positive stress test, we feel the smaller increases in LVEF in CAD patients were due to LV scarring secondary to remote myocardial infarctions. Finally, whether or not LVEF increased by $\geq +7$ EFUs did not depend upon the maximum tolerated dose of beta-blocker (94% took carvedilol), as the mean daily dose differed by only 0.5 mg.

Autonomic (P&S and HRV) measures have been documented to be associated with LVEF and cardiovascular risk (32). Table VI presents the P&S and LVEF data without regard to clinical outcomes. RANCHF patients demonstrated a decrease in SB from 2.42 to 1.98 ($p = 0.019$) mainly resulting from a reduction in LFa, for example, a sympatholytic effect. Sympatholytics, such as beta-blockers, are known to be cardioprotective. This protection is at least in part due to a decrease in SB (balance) toward 1.0 indicating less sympathetic activity and a relative increase in parasympathetic activity (33). and it is associated with reduced CAN risk. NORANCHF patients almost doubled their initially high-normal SB as a result of a marked increase in LFa with only a small increase in RFa, increasing the risk for MACE. The ANS responses to standing were more normal after RAN, indicating improved ANS function and reduced risk of orthostasis. Orthostasis not uncommonly limits the doses of beta-blockers and ACE-Is/ARBs CHF patients can tolerate. Conversely, NORANCHF patients on average displayed a more

abnormal standing response during follow-up, resulting from a decrease in LFa (SW) consistent with worsening of ANS function, increasing the risk for orthostasis. In contrast to the dramatic LFa changes noted in both groups, RFa (parasympathetic) activity changes were very small, consistent with the lack of significant changes in the Time Domain Ratios, and CAN was not, on average, improved. The lack of a significant impact upon CAN means RAN's reduction of SB might be an important mitigating factor reducing the CV risk of CAN. Differences in ANS measures in patients with or without events are presented in Tables IV and V.

While this study was an open enrollment (nonrandomized) trial and underpowered to make final health outcome assessments, we found a qualitative reduction in the composite endpoint of cardiac death, CHF admissions and therapies for Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) in the RANCHF group. There was a 40% event reduction, with 57% fewer deaths, 60% fewer VT/VF therapies and 20% fewer CHF hospitalizations. The initial LVEF was lower in MACE patients than in non-MACE patients (Tabs. V and VI). Only the RANCHF group increased LVEF during follow-up, and the increase was more in patients without events. The increase in MACE patients' LVEF (Tab. IV) was the same as the LVEF increase of the entire systolic RANCHF group (Tab. II), yet RANCHF patients had 40% fewer events. Therefore, high sympathetic activity as indicated by high SB was more predictive of MACE than a change in LVEF. When SB was ≤ 2.5 or LVEF was ≥ 0.32 , 81% or 79% of subjects, respectively, were MACE-free; when SB was > 2.5 , 59% of patients suffered MACE vs. 50% of patients when LVEF was < 0.32 .

Limitations

This is a single-center study. Recently, it was proposed that diastolic CHF be defined as CHF with $LVEF \geq 0.50$ (10). Had we used this definition, only one of our diastolic RANCHF patients would have remained, increasing the systolic RANCHF group to 50 patients. With a new definition of systolic CHF requiring an $LVEF < 0.50$ (instead of ≤ 0.40), RAN would have increased $LVEF \geq +7$ EFUs in 26/53 (49%) systolic CHF patients, an increase from the 14/41 (34%) herein reported ($p < 0.001$), with RAN being the last add-on therapy.

Using spectral analysis of HRV to estimate cardiac sympathetic activity in CHF has its limitations. The sinoatrial node becomes less responsive to norepinephrine and acetylcholine, so HRV decreases despite high norepinephrine levels (34). Therefore, absolute cardiac LFa is inversely related to sympathetic outflow to muscle. Spectral analysis measures the modulation of autonomic neural outflow to the heart. SB reflects this modulation, and an $SB > 2.5$ has a positive predictive value of 61% for MACE. In comparison to¹²³ Iodine, Metaiodobenzylguanidine (MIBG) imaging to assess cardiac sympathetic activity, only 29% of CHF patients with high MIBG washout suffered MACE within a mean follow-up of 31 months (35).

Conclusions

RAN preserved or improved LVEF during a 24 month follow-up period when added to guideline-driven therapy in CHF. Since LVEF has long been considered one of the most

important prognostic indicators in CHF, and since RAN seems free of the potentially harmful side effects of some of the agents that increase LVEF (such as catecholamines and phosphodiesterase inhibitors), RAN has the potential to improve CHF mortality and morbidity without significant adverse effects. Reduced sympathetic tone (LFa) and SB were present in RANCHF patients; the lowest measures of both were in RAN-treated patients without MACE. When SB was ≤ 2.5 , only 19% of subjects experienced MACE. High SB with low RFa (< 0.1 bpm², defined as CAN) is associated with increased mortality and morbidity risk. Therefore measuring P&S function should improve our ability to risk-stratify our patients and adjust their management accordingly. Periodic P&S measures have become just as a routine management tool in our CHF patients as assessment of LVEF or measurement of (pro-)brain natriuretic peptide.

Disclosures

Financial support: No grants or funding have been received for this study.

Conflict of interest: Dr. Colombo is a part owner, employee, Medical Director and Executive VP of ANSAR Medical Technologies, Inc.

References

1. Flather MD, Yusuf S, Køber L, et al.; ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. *Lancet*. 2000;355(9215):1575-1581.
2. Granger CB, McMurray JJ, Yusuf S, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet*. 2003;362(9386):772-776.
3. Cohn JN, Tam SW, Anand IS, Taylor AL, Sabolinski ML, Worcel M; A-HeFT Investigators. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. *J Card Fail*. 2007;13(5):331-339.
4. Fagerberg B for the MERIT-CHF Study Group. Effect of Metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). *Lancet*. 1999;353(9169):2001-2007.
5. Packer M, Coats AJ, Fowler MB, et al.; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med*. 2001;344(22):1651-1658.
6. Kadish A, Mehra M. Heart failure devices: implantable cardioverter-defibrillators and biventricular pacing therapy. *Circulation*. 2005;111(24):3327-3335.
7. Shryock JC, Belardinelli L. Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium. *Br J Pharmacol*. 2008;153(6):1128-1132.
8. Wang GK, Calderon J, Wang SY. State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na⁺ channel isoforms by ranolazine. *Mol Pharmacol*. 2008;73(3):940-948.
9. Rajamani S, Shryock JC, Belardinelli L. Block of tetrodotoxin-insensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na⁺ channels by ranolazine. *Channels (Austin)*. 2008;2(6):449-460.



10. Hunt S, Abraham W, Chin M, et al. ACC/AHA guidelines update for the diagnosis and management of chronic heart failure in the adult: Summary article. *Circulation*. 2007;115:1825-1852.
11. Albin G, Rahko PS. Comparison of echocardiographic quantitation of left ventricular ejection fraction to radionuclide angiography in patients with regional wall motion abnormalities. *Am J Cardiol*. 1990;65(15):1031-1032.
12. Himelman RB, Cassidy MM, Landzberg JS, Schiller NB. Reproducibility of quantitative two-dimensional echocardiography. *Am Heart J*. 1988;115(2):425-431.
13. Lang RM, Bierig M, Devereux RB, et al.; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *J Am Soc Echocardiogr*. 2005;18(12):1440-1463.
14. Ewing DJ. Cardiovascular reflexes and autonomic neuropathy. *Clin Sci Mol Med*. 1978;55(4):321-327.
15. Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. *Science*. 1981;213(4504):220-222.
16. Akselrod S, Gordon D, Madwed JB, Snidman NC, Shannon DC, Cohen RJ. Hemodynamic regulation: investigation by spectral analysis. *Am J Physiol*. 1985;249(4 Pt 2):H867-H875.
17. Akselrod S, Eliash S, Oz O, Cohen S. Hemodynamic regulation in SHR: investigation by spectral analysis. *Am J Physiol*. 1987;253(1 Pt 2):H176-H183.
18. Akselrod S. Spectral analysis of fluctuations in cardiovascular parameters: a quantitative tool for the investigation of autonomic control. *Trends Pharmacol Sci*. 1988;9(1):6-9.
19. Aysin B, Aysin E. Effect of respiration in heart rate variability (HRV) analysis. 28th Annual International Conference of IEEE Engineering in Medicine and Biology Society, New York, NY, September 2006.
20. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. *Circulation*. 2007;115(3):387-397.
21. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. *Diabetes Care*. 2003;26(6):1895-1901.
22. Low PA, ed. *Clinical autonomic disorders: evaluation and management*. Philadelphia, PA: Lippincott-Raven; 1997.
23. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? *Circ Res*. 2004;95(8):754-763.
24. Watanabe J, Shinozaki T, Shiba N, et al. Accumulation of risk markers predicts the incidence of sudden death in patients with chronic heart failure. *Eur J Heart Fail*. 2006;8(3):237-242.
25. Curtis BM, O'Keefe JH Jr. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. *Mayo Clin Proc*. 2002;77(1):45-54.
26. Nanavati SH, Bulgarelli RJ, Vazquez-Tanus J, Ghosh-Dastidar S, Colombo J, Arora RR. Altered autonomic activity with atrial fibrillation as demonstrated by non-invasive autonomic monitoring. *US Cardiology*. 2010;7(1):47-50.
27. Malik M; Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. *Circulation*. 1996;93(5):1043-1065.
28. Dib N, Michler RE, Pagani FD, et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. *Circulation*. 2005;112(12):1748-1755.
29. Maier LS, Layug B, Karwatowska-Prokopczuk E, et al. RANO-Lazlne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. *JACC Heart Fail*. 2013;1(2):115-122.
30. Rector TS, Cohn JN. Prognosis in congestive heart failure. *Annu Rev Med*. 1994;45:341-350.
31. El-Kadri M, Sharaf-Dabbagh H, Ramsdale D. Role of antiischemic agents in the management of non-ST elevation acute coronary syndrome (NSTEMI-ACS). *Cardiovasc Ther*. 2012;30(1):e16-e22.
32. Liu Y, Syed Z, Scirica BM, Morrow DA, Guttag JV, Stultz CM. ECG morphological variability in beat space for risk stratification after acute coronary syndrome. *J Am Heart Assoc*. 2014;3(3):e000981.
33. Umetani K, Singer DH, McCraty R, Atkinson M. Twenty-four hour time domain heart rate variability and heart rate: relations to age and gender over nine decades. *J Am Coll Cardiol*. 1998;31(3):593-601.
34. Notarius CF, Floras JS. Limitations of the use of spectral analysis of heart rate variability for the estimation of cardiac sympathetic activity in heart failure. *Europace*. 2001;3(1):29-38.
35. Boogers MJ, Veltman CE, Bax JJ. Cardiac autonomic nervous system in heart failure: imaging technique and clinical implications. *Curr Cardiol Rev*. 2011;7(1):35-42.